Natera, Inc. is a company within the Biotechnology / Healthcare category. Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in genetic testing for prenatal health, oncology, and organ health. The company utilizes proprietary molecular biology and bioinformatics to provide non-invasive insights into human health and disease management.
Natera, Inc. was founded in 2004 and is headquartered in Austin, TX.
Natera, Inc. is part of Independent Publicly Traded.
Natera, Inc. is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Natera, Inc. is Strong. Significant factual deltas detected.
AI models classify Natera, Inc. as a Challenger. AI names competitors first.
Natera, Inc. appeared in 7 of 8 sampled buyer-intent queries (88%). Natera dominates branded searches but faces competition from Labcorp and Guardant Health in unbranded clinical queries.
AI provides highly accurate technical descriptions of Natera's genetic testing capabilities and market position. However, it may struggle to keep pace with the rapidly evolving oncology clinical data and specific regulatory milestones for new test indications. Key gap: The transition from a primarily women's health-focused company to a leader in oncology and organ health monitoring is often lagged in general AI summaries.
Of 5 key facts verified about Natera, Inc., 4 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Geographic data regarding headquarters and laboratory locations due to recent corporate expansions and relocations.
Buyers turn to Natera, Inc. for Standard OB/GYN Care: Standard prenatal care through obstetricians without genetic screening support., Invasive Diagnostic Procedures: Invasive diagnostic procedures like Amniocentesis or Chorionic Villus Sampling (CVS)., among 2 documented problem areas.
Buyers evaluating Natera, Inc. typically ask AI models about "non-invasive prenatal testing providers", "MRD testing for colorectal cancer", "personalized liquid biopsy oncology", and 3 similar queries.
Natera, Inc.'s main competitors are Guardant Health. According to AI models, these are the brands most frequently named alongside Natera, Inc. in buyer-intent queries.
Natera, Inc.'s core products are Panorama NIPT, Signatera MRD Test, Prospera Organ Health, Horizon Carrier Screening.
Natera, Inc. uses Usage-based / Insurance Billing / Patient Self-Pay.
Natera, Inc. serves OB/GYNs, Oncologists, Nephrologists, Health Systems, and Expectant Parents..
Natera, Inc. A proprietary SNP-based (Single Nucleotide Polymorphism) technology platform that provides higher sensitivity and fetal fraction detection than standard counting methods.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/natera
Last analyzed: April 10, 2026
Founded: 2004
Headquarters: Austin, Texas, USA